Terms: = Lung cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Prognosis
246 results:
1. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
2. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
3. Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature.
Bradová M; Mosaieby E; Michal M; Vaněček T; Ing SK; Grossmann P; Koshyk O; Kinkor Z; Laciok Š; Nemcová A; Straka Ľ; Farkas M; Michal M; Švajdler M
Histopathology; 2024 Apr; 84(5):776-793. PubMed ID: 38114270
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
5. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
[TBL] [Abstract] [Full Text] [Related]
6. CBX4 deletion promotes tumorigenesis under Kras
Chen F; Hou W; Yu X; Wu J; Li Z; Xu J; Deng Z; Chen G; Liu B; Yin X; Yu W; Zhang L; Xu G; Ji H; Liang C; Wang Z
Signal Transduct Target Ther; 2023 Sep; 8(1):343. PubMed ID: 37696812
[TBL] [Abstract] [Full Text] [Related]
7. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract] [Full Text] [Related]
8. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
Borea F; Franczak MA; Garcia M; Perrino M; Cordua N; Smolenski RT; Peters GJ; Dziadziuszko R; Santoro A; Zucali PA; Giovannetti E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298116
[TBL] [Abstract] [Full Text] [Related]
9. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China.
Zhang C; Wu H; Xu G; Xu Y; Ma W; Li Z; Zhang J
BMC Cancer; 2023 Jun; 23(1):506. PubMed ID: 37271825
[TBL] [Abstract] [Full Text] [Related]
10. TP53 or cdkn2a/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
[TBL] [Abstract] [Full Text] [Related]
11. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract] [Full Text] [Related]
12. Significance of cuproptosis-related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach.
Yang L; Cui Y; Liang L; Lin J
Thorac Cancer; 2023 Jun; 14(16):1451-1466. PubMed ID: 37076991
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract] [Full Text] [Related]
14. The cytological features of effusions with mesothelioma in situ: A report of 9 cases.
Michael CW; Bedrossian CCWM; Sadri N; Klebe S
Diagn Cytopathol; 2023 Jun; 51(6):374-388. PubMed ID: 36942732
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Value of EMT Gene Signature in Malignant Mesothelioma.
Wu L; Yoshihara K; Yun H; Karim S; Shokri N; Zaeimi F; Man HSJ; Zia A; Felley-Bosco E; de Perrot M
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901697
[TBL] [Abstract] [Full Text] [Related]
16. Pharmacological inhibition of EZH2 by ZLD1039 suppresses tumor growth and pulmonary metastasis in melanoma cells in vitro and in vivo.
Zhu Y; Zhang L; Song X; Zhang Q; Wang T; Xiao H; Yu L
Biochem Pharmacol; 2023 Apr; 210():115493. PubMed ID: 36898415
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.
Mehanna H; Taberna M; von Buchwald C; Tous S; Brooks J; Mena M; Morey F; Grønhøj C; Rasmussen JH; Garset-Zamani M; Bruni L; Batis N; Brakenhoff RH; Leemans CR; Baatenburg de Jong RJ; Klussmann JP; Wuerdemann N; Wagner S; Dalianis T; Marklund L; Mirghani H; Schache A; James JA; Huang SH; O'Sullivan B; Nankivell P; Broglie MA; Hoffmann M; Quabius ES; Alemany L;
Lancet Oncol; 2023 Mar; 24(3):239-251. PubMed ID: 36796393
[TBL] [Abstract] [Full Text] [Related]
18. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
[TBL] [Abstract] [Full Text] [Related]
19. The cytologic diagnosis of mesothelioma: are we there yet?
Michael CW
J Am Soc Cytopathol; 2023; 12(2):89-104. PubMed ID: 36702736
[TBL] [Abstract] [Full Text] [Related]
20. Construction and Validation of Early Warning Model of lung cancer Based on Machine Learning: A Retrospective Study.
Ye S; Pan J; Ye Z; Cao Z; Cai X; Zheng H; Ye H
Technol Cancer Res Treat; 2022; 21():15330338221136724. PubMed ID: 36380607
[No Abstract] [Full Text] [Related]
[Next]
